JTK 003Alternative Names: JTK-003
Latest Information Update: 30 Mar 2007
At a glance
- Originator Japan Tobacco
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 31 Aug 2005 Discontinued - Phase-II for Hepatitis C (PO)
- 01 Aug 2005 Discontinued - Phase-II for Hepatitis C in Japan (PO)
- 09 Aug 2004 Phase-II clinical trials in Hepatitis C (PO)